Published in Cancer Weekly, September 7th, 2004
Revenues for the second quarter of 2004 were $212,000 compared to $1.8 million for the quarter ended June 30, 2003.
The decrease in revenue for the quarter ended June 30, 2004 was attributable to the termination of Dendreon's collaboration with Kirin Brewery Co., Ltd., in November 2003. Revenues for the six months ended June 30, 2004 were $4.9 million compared to $3.6 million for the six months ended June 30, 2003. Revenues in the six months ended June 30, 2004 were primarily from Dendreon's license agreement with Nuvelo, Inc., for Dendreon's novel anticoagulant, recombinant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.